TDO2 and ovarian cancer: To investigate the relative contributions of IDO1 versus TDO2, we generated shRNA-mediated knockdown IDO1 and TDO2, as well as the downstream KYN receptor AhR in human ovarian cancer OVCAR3 cells (Fig. 2A and B).